BIOMARKER FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) - Yamamoto et al 27 Feb 2020

Sly Saint · Mar 2, 2020

Abstract
(EN)
A method for diagnosing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is provided in the present disclosure. The present disclosure provides a method that uses the B cell receptor (BCR) repertoire as an indicator of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). One or more variables selected from the group consisting of the frequency of use of one or more genes in the IgGH heavy chain variable region of the BCR in a subject, the BCR diversity index in a subject, and the level of one or more immune cell subpopulations in a subject can be used as an indicator of ME/CFS in the subject.
Click to expand...

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020040210&tab=PCTBIBLIO

(main paper in japanese)

Trish · Mar 2, 2020

Looks like it's a patent application, not a research paper.

Wits_End · Mar 2, 2020

It is, but if they've got as far as filing a patent application, then surely they've done quite a bit of research beforehand?

Hutan · Mar 2, 2020

Inventors

山村　隆 YAMAMURA Takashi; JP

佐藤　和貴郎 SATO Wakiro; JP

小野　紘彦 ONO Hirohiko; JP

松谷　隆治 MATSUTANI Takaji; JP

中村　征史 NAKAMURA Yukio; JP

北浦　一孝 KITAURA Kazutaka; JP

Agents

山本　秀策 YAMAMOTO Shusaku; JP

森下　夏樹 MORISHITA Natsuki; JP

▲駒▼谷　剛志 KOMATANI Takeshi; JP

飯田　貴敏 IIDA Takatoshi; JP

石川　大輔 ISHIKAWA Daisuke; JP

山本　健策 YAMAMOTO Kensaku; JP

Yamamoto is the first listed agent, but it's probably the inventor names that we are likely to find on papers.

There's a T Yamamura who was a joint author with Komaroff, discussed here:
Neuroinflammation/PET research out of Japan

This thread mentions Wakiro Sato
https://www.s4me.info/threads/fundi...diagnosis-method-for-me-cfs.9064/#post-159900

Japan Medical Research and Development Organization decided to provide funding for the following research. Project title:"Development of blood diagnosis method for ME / CFS" Organization:National Center Hospital, National Center of Neurology and Psychiatry Representative: Wakiro Sato MD, PhD Period: April 2019-March 2020
Click to expand...

alex3619 · Mar 3, 2020

Wits_End said: ↑

It is, but if they've got as far as filing a patent application, then surely they've done quite a bit of research beforehand?
Click to expand...

Sometimes, but the priority is to nail down the finding as a patent before doing the research and potentially giving the game away, where competitors can steal a march on them. So if you even suspect a useful finding, you patent it. I suspect most such patents never work out, and you never hear of them again.

mariovitali · Mar 3, 2020

I always believed that taking Japanese language lessons would be put to use one day :

[Claim 1]
　A method of using a B cell receptor (BCR) repertoire in a subject as an indicator of myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) in the subject.
[Claim 2]
　Claims: One or more variables, including the frequency of use of one or more genes in the IgGR chain variable region of the BCR in a subject, are indicative of myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) in the subject. Item 2. The method according to Item 1.
[Claim 3]
　3. The method of claim 2, further comprising the one or more variables being an indication that the subject has ME / CFS rather than another disease.
[Claim 4]
　The one or more genes are IGHV1-2, IGHV1-3, IGHV1-8, IGHV1-18, IGHV1-24, IGHV1-38-4, IGHV1-45, IGHV1-46, IGHV1-58, IGHV1-69, IGHV1-69-2, IGHV1-69D, IGHV1 / OR15-1, IGHV1 / OR15-5, IGHV1 / OR15-9, IGHV1 / OR21-1, IGHV2-5, IGHV2-26, IGHV2-70, IGHV2-70D, IGHV2 / OR16-5, IGHV3-7, IGHV3-9, IGHV3-11, IGHV3-13, IGHV3-15, IGHV3-16, IGHV3-20, IGHV3-21, IGHV3-23, IGHV3-23D, IGHV3-25, IGHV3-30, IGHV3-30-3, IGHV3-30-5, IGHV3-33, IGHV3-35, IGHV3-38, IGHV3-38-3, IGHV3-43, IGHV3-43D, IGHV3-48, IGHV3-49, IGHV3-53, IGHV3-64, IGHV3-64D, IGHV3-66, IGHV3-72, IGHV3-73, IGHV3-74, IGHV3-NL1, IGHV3 / OR15-7, IGHV3 / OR16-6, IGHV3 / OR16-8, IGHV3 / OR16-9, IGHV3 / OR16-10, IGHV3 / OR16-12, IGHV3 / OR16-13, IGHV4-4, IGHV4-28, IGHV4-30-2, IGHV4-30-4, IGHV4-31, IGHV4- 34, IGHV4-38-2, IGHV4-39, IGHV4-59, IGHV4-61, IGHV4 / OR15-8, IGHV5-10-1, IGHV5-51, IGHV6-1, IGHV7-4-1, IGHV7-81, IGHD1-1, IGHD1-7, IGHD1-14, IGHD1-20, IGHD1-26, IGHD1 / OR15-1a / b, IGHD2-2 , IGHD2-8, IGHD2-15, IGHD2-21, IGHD2 / OR15-2a / b,
[Claim 5]
　The one or more genes are IGHV3-73, IGHV1-69-2, IGHV5-51, IGHV4-31, IGHV3-23D, IGHV1 / OR15-9, IGHV4-39, IGHD5-12, IGHV3-43D, IGHD4- 17, IGHV5-10-1, IGHD4 / OR15-4a / b, IGHG4, IGHV1 / OR15-5, IGHV3 / OR16-9, IGHD1-7, IGHV3-21, IGHD6-6, IGHV3-33, IGHD4-23, IGHV3-30-5, IGHV3-23, IGHD6-13, IGHV3-64D, IGHV3-48, IGHV3-64, IGHG1, IGHV3-49, IGHV3-30-3, IGHD1-26, IGHJ6, IGHV3-30, IGHGP, The method according to claim 4, comprising at least one gene selected from the group consisting of IGHV1-3 and IGHD3-22.
[Claim 6]
　The one or more genes are IGHD6-6, IGHV3-33, IGHD4-23, IGHV3-30-5, IGHV3-23, IGHD6-13, IGHV3-64D, IGHV3-48, IGHV3-64, IGHG1, IGHV3- The method according to claim 5, comprising at least one gene selected from the group consisting of 49, IGHV3-30-3, IGHD1-26, IGHJ6, IGHV3-30, IGHGP, IGHV1-3 and IGHD3-22.
[Claim 7]
　The one or more genes include at least one gene selected from the group consisting of IGHV3-49, IGHV3-30-3, IGHD1-26, IGHJ6, IGHV3-30, IGHGP, IGHV1-3 and IGHD3-22. The method of claim 6, wherein:
[Claim 8]
　The method according to claim 7, wherein the one or more genes include at least one gene selected from the group consisting of IGHV1-3, IGHV3-30, IGHV3-30-3, IGHV3-49, IGHD1-26 and IGHJ6. the method of.
[Claim 9]
　3. The method of claim 2, wherein the one or more variables further comprises one or more immune cell subpopulation quantities.
[Claim 10]
　10. The method of claim 9, wherein the one or more variables show AUC> 0.7 in a ROC curve by regression analysis for discrimination between normal controls and ME / CFS.
[Claim 11]
　The method of claim 10, wherein the one or more variables show AUC ≧ 0.8 in a ROC curve by regression analysis for discriminating between a normal control and ME / CFS.
[Claim 12]
　The amount of the immune cell subpopulation is the amount of B cells, the amount of naive B cells, the amount of memory B cells, the amount of plasma blasts, the amount of activated naive B cells, the amount of transitional B cells, the amount of regulatory T cells. The amount is selected from the group consisting of an amount, an amount of memory T cells, an amount of follicular helper T cells, an amount of Tfh1 cells, an amount of Tfh2 cells, an amount of Tfh17 cells, an amount of Th1 cells, an amount of Th2 cells, and an amount of Th17 cells. Item 12. The method according to any one of items 9 to 11.
[Claim 13]
　3. The method of claim 2, wherein the one or more variables comprises the frequency of use of two or more genes in the BCR IgG chain variable region in the subject.
Click to expand...

Snow Leopard · Mar 3, 2020

Looks like patent gaming to me...

Log in or Sign up

BIOMARKER FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) - Yamamoto et al 27 Feb 2020

Sly Saint Senior Member (Voting Rights)

Trish Moderator Staff Member

Wits_End Senior Member (Voting Rights)

Hutan Moderator Staff Member

alex3619 Senior Member (Voting Rights)

mariovitali Senior Member (Voting Rights)

Snow Leopard Senior Member (Voting Rights)

Share This Page

Log in or Sign up

BIOMARKER FOR MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) - Yamamoto et al 27 Feb 2020

Sly Saint Senior Member (Voting Rights)

Trish Moderator Staff Member

Wits_End Senior Member (Voting Rights)

Hutan Moderator Staff Member

alex3619 Senior Member (Voting Rights)

mariovitali Senior Member (Voting Rights)

Snow Leopard Senior Member (Voting Rights)

Share This Page

Useful Searches